The BCA-1 Test analyses DNA in a urine sample for genomic alterations in the sequence of DNA in chromosomes.
The results are based on the level of genomic alterations observed across all chromosomes as identified by ArrayGenomics’ clinical research to validate the BCA-1 Test. They correlate chromosomal activity with the probability of non muscle-invasive bladder cancer as defined in the World Health Organisation (WHO) guidelines.
The BCA-1 Test has been shown in clinical trials to detect the presence of bladder cancer with overall sensitivity of 95%.
The BCA-1 Test also looks in particular at 27 genomic sequences - or markers - which are known to be involved in bladder cancer. These may be useful for your doctor to help plan your treatment.
The BCA-1 Test is the only bladder cancer test to analyse 27 genomic markers covering all known bladder cancers.
High genomic activity: Consistent with a probability of high grade, non muscle-invasive bladder cancer.
Low genomic activity: Consistent with a probability of low grade, non muscle-invasive bladder cancer.
No genomic activity: No genomic activity recorded
The BCA-1 report also gives more information about the genomic alterations present and contains analysis from our specialist urologists that your doctor may wish to use to manage your treatment.
The BCA-1 Test has an overall sensitivity of 95% which is the highest of all bladder cancer tests currently available.
Read more about sensitivity here.
The BCA-1 Test is most effective in non-muscle-invasive (superficial) bladder cancer which needs close active surveillance in order to detect potential recurrence.
It is not intended as a diagnostic test. If you are concerned about symptoms or think you might be at risk of bladder cancer, you should see a doctor as soon as possible.
Although there have been some instances where the BCA-1 Test has been able to reveal bladder cancer before it was detected by cystoscopy (the standard diagnostic procedure used in bladder cancer) the test is not currently recognised as a diagnostic tool and we recommend that you always follow the advice of your doctor.
This test cannot be used to monitor other cancers, such as prostate, kidney or bowel.
Download the clinical study to validate the BCA-1 test - Cussenot, et al. 2014